Common rapid-acting insulins include menopausal insulin and lysergic insulin. Diabetic patients have absolute or relative insufficiency of insulin in their bodies, so they can be treated with exogenous insulin when necessary. Clinically, they are categorized into ultra-short-acting (also known as fast-acting), short-acting, intermediate-acting, long-acting, and premixed insulin according to the rapidity of onset of action and maintenance time. Common rapid-acting insulins include insulin menthyl and insulin lysine. Rapid-acting insulin is characterized by fast action and short duration of action, and should be administered within 0-15 minutes before or immediately after meals. It is usually injected subcutaneously, and the site can be thigh or abdominal wall, buttock or arm. Adverse effects such as hypoglycemia, rash, edema, and lipoatrophy may occur with rapid-acting insulin, and blood glucose must be monitored regularly during use. It is contraindicated in patients who are allergic to insulin or any other ingredient contained in this product, and is contraindicated in the event of hypoglycemia. The insulin use program should be formulated by a professional doctor according to the condition of each patient, and should not be used without authorization.